drugset
drugset / Trial / NCT00002579

Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer

NCT00002579 ↗

Phase 3 Completed 2000 enrolled Scottish Cancer Therapy Network
RandomizedTreatment

Summary

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. Combining combination chemotherapy with hormone therapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without tamoxifen in treating women with stage I or stage II breast cancer that can be surgically removed.

Timeline

Start
1993-03
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Tamoxifen Small molecule — Oral
Background Cyclophosphamide Other / unclassified — —
Background Methotrexate Small molecule — —
Background fluorouracil Small molecule — —

Indications

breast cancer